Hunt Investment Group

Hunt Growth Capital is the private equity division of Hunt Consolidated, Inc., focusing on direct investments and investments in other funds. The firm avoids sectors such as oil and gas, domestic U.S. real estate, and utilities. In its direct investments, Hunt Growth Capital targets growth capital, buyouts, and acquisitions in early middle-market companies, typically investing between $2 million and $6 million for minority stakes of 25% or more in companies with revenues ranging from $10 million to $25 million and EBITDA of up to $3 million. The firm is geographically diverse, preferring investments in the Southwest and Southeast U.S., while also considering opportunities in Western Europe and Japan for fund investments. For fund investments, Hunt Growth Capital generally invests between $1 million and $5 million in funds with at least $100 million in assets under management, although it may consider smaller funds in special circumstances. The firm aims to take active roles on the boards of its portfolio companies and prefers senior equity investments with shorter lock-up periods. Hunt Growth Capital is headquartered in Dallas, Texas.

Scott H. Colvert

Partner

3 past transactions

Bitwise Industries

Series B in 2021
Bitwise Industries Inc. is a technology ecosystem company based in Fresno, California, focused on enhancing the local technology landscape. Established in 2013, the company operates Geekwise Academy, which provides accelerated coding education aimed at individuals of all ages, particularly from marginalized backgrounds. In addition to educational services, Bitwise Industries runs a custom software development firm, Shift3 Technologies, that connects experienced developers with entry-level programmers to create software solutions. The company also fosters community and collaboration by developing tech venues and co-working spaces that serve as hubs for technologists and technology companies. Through these initiatives, Bitwise Industries aims to empower individuals with vital tech skills and create pathways to meaningful careers in the technology sector.

Cudoni

Venture Round in 2020
Cudoni is a premier serviced luxury marketplace operating in the UK and Europe, specializing in the buying and selling of pre-loved luxury items. The company utilizes data and technology to streamline the sales process, offering comprehensive services that include item collection, market valuations, professional photography, detailed descriptions, authentication, storage, and fulfillment. Cudoni's expertise allows sellers to achieve sales prices that are 30-50% higher on average compared to self-sales, addressing challenges posed by counterfeits in the second-hand luxury market. For those seeking immediate transactions without the hassle of consignment, Cudoni provides an 'Instant Purchase' option. By exclusively controlling its inventory, the marketplace ensures that buyers have access to a curated selection of high-demand products, accompanied by guarantees of authenticity and quality, available for next-day delivery.

Silverback Therapeutics

Series B in 2020
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.